Results 241 to 250 of about 98,929 (291)

A membranous nephropathy variant mimicking minimal change disease

open access: yesThe Journal of Pathology: Clinical Research, Volume 12, Issue 1, January 2026.
Abstract This study characterizes a novel disease pattern of membranous nephropathy (MN) that exhibits overlapping clinicopathological features with minimal change disease (MCD), termed ‘MCD‐like MN’. Patients with histologically confirmed MN showing sparse and segmental subepithelial electron‐dense deposits (EDD) but clinically resembling MCD were ...
Chuqi Pan   +8 more
wiley   +1 more source

Short‐term actions of epigalocatechin‐3‐gallate in the liver: a mechanistic insight into hypoglycemic and potential toxic effects

open access: yesFEBS Open Bio, Volume 16, Issue 1, Page 199-221, January 2026.
Epigallocatechin‐3‐gallate (EGCG) acutely inhibited gluconeogenesis and enhanced glycolysis, glycogenolysis, and fatty acid oxidation in perfused rat livers. Mechanistic assays revealed mitochondrial uncoupling, inhibition of pyruvate carboxylation and glucose‐6‐phosphatase, shift of NADH/NAD+ ratios toward oxidation, and loss of membrane integrity ...
Carla Indianara Bonetti   +8 more
wiley   +1 more source

CypA Mediates Non‐Small Cell Lung Cancer Chemoresistance by Attenuating Ferroptosis via Stabilizing SLC7A11

open access: yesAdvanced Science, Volume 13, Issue 4, 19 January 2026.
Summary diagram for the role of CypA in chemoresistance in non‐small cell lung cancer (NSCLC). CypA is overexpressed in chemoresistance NSCLC and drives therapeutic evasion by competitively binding to the K37 site of SLC7A11, thereby blocking TRIM3 mediated K11‐linked ubiquitination and proteasomal degradation, ultimately inhibiting lipid peroxidation ...
Zhongcheng Wang   +9 more
wiley   +1 more source

Versatile sugar and valerate metabolic pathways in Paraburkholderia xenovorans LB400 enable tailored poly(3-hydroxybutyrate-co-3-hydroxyvalerate) production. [PDF]

open access: yesAppl Microbiol Biotechnol
Sepúlveda MI   +10 more
europepmc   +1 more source

Genome‐scale Metabolic Modeling Guided Escherichia coli Engineering for De Novo Biosynthesis of Chrysanthemic Acid

open access: yesAdvanced Science, Volume 13, Issue 2, 9 January 2026.
Genome‐scale metabolic modeling is preceded to the engineered E. coli cell factory for the de novo biosynthesis of biopesticide chrysanthemic acid. The debranching strategy redirects metabolic flux, enhancing precursor and target compound production.
Jiangpeng Yu   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy